LATEST ARTICLES

October 1, 2014: Head-to-head Phase III trial demonstrates superior progression-free survival of afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

Created on: Wednesday, October 01, 2014

LUX-Lung 8 trial met its primary endpoint of improving progression-free survival in patients treated with afatinib versus erlotinib after failure of first-line, platinum-based chemotherapy, reducing the risk of disease progression by 18%

(Read More)

October 1, 2014: You can now track the billions that drug companies pay doctors and hospitals

Created on: Wednesday, October 01, 2014

For the first time Tuesday afternoon, there's new sunshine on the financial ties between drug and device companies and the doctors and teaching hospitals they target to use their products.

(Read More)

October 1, 2014: Does the Open Payments Database ‘Distort’ What Docs Get For Research?

Created on: Wednesday, October 01, 2014

Another day and another complaint is being lodged about the Open Payments database.

(Read More)

October 1, 2014: Find Out How Much Money Your Doctor Took From Drug Companies

Created on: Wednesday, October 01, 2014

New data revealing the payments doctors and teaching hospitals received from drug companies and device manufacturers was made available online on Tuesday, the Centers for Medicare and Medicaid Services announced.

(Read More)

October 1, 2014: Our First Dive Into the New Open Payments System

Created on: Wednesday, October 01, 2014

The government’s data on payments to doctors and hospitals by drug and device makers is incomplete and hard to penetrate – but here’s a first look.

(Read More)

October 1, 2014: Second Court Strikes Down Obamacare Subsidies In Federal Exchanges

Created on: Wednesday, October 01, 2014

Another federal court has struck down an IRS rule that gives Obamacare subsidies to customers in federally-run exchanges.

(Read More)

October 1, 2014: New Guideline from ASCO on Use of Chemotherapy and Targeted Therapy for Patients with HER2-Neg Advanced Breast Cancer

Created on: Wednesday, October 01, 2014

The American Society of Clinical Oncology has issued a new clinical practice guideline on the use of chemotherapy and targeted therapy for women with human epidermal growth factor 2 (HER2)-negative (or unknown) locally advanced and/or metastatic breast cancer who are being considered for treatment with chemotherapy and/or targeted therapy.

(Read More)

September 30, 2014: Did Changes in Drug Reimbursement After the Medicare Modernization Act Affect Chemotherapy Prescribing?

Created on: Tuesday, September 30, 2014

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) decreased fee-for-service (FFS) payments for outpatient chemotherapy. We assessed how this policy affected chemotherapy in FFS settings versus in integrated health networks (IHNs).

(Read More)

September 30, 2014: Study: Cancer costs 'skyrocketed' despite drug cuts

Created on: Tuesday, September 30, 2014

The cost of treating cancer has "skyrocketed" despite a 2003 law that sought to control Medicare drug costs, including the cost of chemotherapy, according to a new study.

(Read More)

September 30, 2014: Johns Hopkins Experts Say Open Payments Database Casts Shadows, Not Light

Created on: Tuesday, September 30, 2014

A federal, public database launched September 30 with the intention of bringing transparency to financial relationships between physicians and industry may instead result in opacity and misinterpretation, according to experts in bioethics, clinical care and public health at Johns Hopkins.

(Read More)

|1| 2 | Next >>

Blog Home

TedOkonCOA TWITTER

Community Oncology Alliance
1101 Pennsylvania Avenue, N.W.
Suite 700
Washington, DC 20004
(202) 756-2258